Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by M. I. Sevilla
Based on 1 article published since 2009
(Why 1 article?)

Between 2009 and 2019, M. I. Sevilla wrote the following article about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Guideline Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors. 2018

Merino-Casabiel, X / Aller, J / Arbizu, J / García-Figueiras, R / González, C / Grande, E / Jiménez-Fonseca, P / Sevilla, M I / Capdevila, J. ·Radiology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain. · Endocrinology Department, Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Spain. · Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, Spain. · Radiology Department, Complexo Hospitalario Universitario de Santiago de Compostela, A Coruña, Spain. · Radiology Department, Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Spain. · Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. · Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain. · Medical Oncology Department, Investigación Clínica y Traslacional en Cáncer, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Universitario Regional y Virgen de la Victoria de Málaga, Malaga, Spain. · Medical Oncology Department and Gastrointestinal and Endocrine Tumor Unit, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035, Barcelona, Spain. jacapdevila@vhebron.net. ·Clin Transl Oncol · Pubmed #29766455.

ABSTRACT: PURPOSE: Gastroenteropancreatic neuroendocrine tumors are a heterogeneous group of low incidence neoplasms characterized by a low proliferative activity and slow growth. Their response to targeted therapies is heterogeneous and often does not lead to tumor shrinkage. Thus, evaluation of the therapeutic response should differ from other kind of tumors. METHODS: To answer relevant questions about which techniques are best in the assessment of progression or treatment response a RAND/UCLA-based consensus process was implemented. Relevant clinical questions were listed followed by a systematic search of the literature. The expert panel answered all questions with recommendations, combining available evidence and expert opinion. Recommendations were validated through a questionnaire and a participatory meeting. RESULTS: Expert recommendations regarding imaging tools for tumor assessment and evaluation of progression were agreed upon. Available imaging techniques were reviewed and recommendations for best patient monitoring practice and the best way to evaluate treatment response were formulated.